Premium
Effect of halofenate on exercise performance in coronary heart disease
Author(s) -
Aronow Wilbert S.,
Harding Phillip R.,
Khurshee Mohammed,
Vangrow Jack S.,
Papageorge's Nicholas P.
Publication year - 1973
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1973143366
Subject(s) - medicine , angina , placebo , cardiology , myocardial infarction , triglyceride , coronary heart disease , significant difference , physical exercise , cholesterol , alternative medicine , pathology
The effect of halofenate, which lowers serum triglyceride but not blood cholesterol, on exercise performance and exercise electrocardiograms was evaluated in 48 patients (31 with angina, 4 with healed myocardial infarction but no angina, and 13 without coranary disease). Four of 17 cardiac patients an placebo and 1 of 18 cardiac patients an halofenate died within 14 months. No significant difference in exercise performance or in the exercise electrocardiograms in patients on halofenate versus patients on placebo was observed at 12 weeks, 24 weeks, 36 weeks, or 48 weeks after medicatian. There was no difference between the effects of halofenate and placebo on exercise electrocardiograms in the patients without angina. Changes in exercise performance or in exercise electrocardiograms were not significantly correlated with changes in serum cholesterol or triglyceride